Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SNPHY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SNPHY and 80,000+ other tickers.
See exactly how SNPHY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SNPHY and 80,000+ other tickers.
Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a significant pipeline and array of products focused on ophthalmic conditions. For glaucoma and ocular hypertension, their drug candidates encompass DE-111, currently undergoing Phase III clinical evaluation; DE-117, which is available in Japan; DE-126, now in Phase IIb trials; DE-128, being developed for European markets and also in Phase II/III…
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Santen Pharmaceutical (OTCMKTS:SNPHY - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Profitability This table compares Otsuka and Santen Pharmaceutical's net
Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,712 shares, a decline of 82.6% from the November 30th total of 27,049 shares. Based on an average trading volume of 13,049